PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)

por Teng, Yue, Tang, Weiyan, Wu, Zhiya, Du, Yuxin, Wu, Jianqiu
Publicado 2023

CMTM3 as a Potential New Immune Checkpoint Regulator

por Shen, Qian, Cong, Zhirong, Zhou, Ying, Teng, Yue, Gao, Jin, Tang, Weiyan
Publicado 2022

Pre‐miR‐27a rs895819 polymorphism and risk of diffuse large B‐cell lymphoma

por Tang, Weiyan, Xu, Haonan, Ma, Dawei, Ma, Rong, Wu, Jianqiu, Yu, Xinnian, Feng, Jifeng, Liu, Qizhan
Publicado 2019

Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen

por Wu, Shenshen, Yang, Xi, Tang, Weiyan, Familiari, Giuseppe, Relucenti, Michela, Aschner, Michael, Li, Xiaobo, Chen, Rui
Publicado 2022

Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report

por Wu, Zhiya, Teng, Yue, Wu, Jianqiu, Zhang, Honglu, Peng, Weiwei, Meng, Cheng, Tang, Weiyan, Feng, Jifeng
Publicado 2022

XRCC1 mediated the development of cervival cancer through a novel Sp1/Krox-20 swich

por Meng, Qingtao, Wang, Shizhi, Tang, Weiyan, Wu, Shenshen, Gao, Na, Zhang, Chengcheng, Cao, Xiaoli, Li, Xiaobo, Zhang, Zhengdong, Aschner, Michael, Jin, Hua, Huang, Yue, Chen, Rui
Publicado 2017

The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy

por Lv, Yan, Du, Yuxin, Li, Kening, Ma, Xiao, Wang, Juan, Du, Tongde, Ma, Yuxin, Teng, Yue, Tang, Weiyan, Ma, Rong, Wu, Jianqiu, Wu, Jianzhong, Feng, Jifeng
Publicado 2023